Comirnaty™ (Pfizer/BioNTech) is a vaccine that protects against COVID-19 disease caused by the SARS-CoV-2 virus.

How Comirnaty is made and what it contains

On this page you will find:

  • What type of vaccine is the Comirnaty vaccine is
  • How mRNA vaccine technology works
  • How the vaccine is made
  • What the vaccine contains

Visit page: How Comirnaty is made and what it contains.


How the vaccine works and the protection it provides

On this page you will find:

  • How mRNA vaccines, like Comirnaty, work
  • How protective is this vaccine?

Visit page: How the vaccine works and the protection it provides.


Comirnaty general resources:

Guidance supporting the administration of mRNA-CV vaccine

Comparison Chart - mRNA-CV Comirnaty vaccines v9

Instructions for multi-dose vial Pfizer/BioNTech vaccine: preparation and administration

Expiry posters

Comirnaty FAQ section:

Please visit here for all frequently answered questions on the Cormirnaty vaccine.

Visit page: Comirnaty FAQ section


High risk 6 months to 4 years old COVID resources 

On this page, you will find resources for vaccinating high risk 6m to 4yrs with Comirnaty (3mcg) 6m-4yrs maroon cap.

Visit page: Comirnaty (3mcg) 6m to 4 years maroon cap COVID resources


5 to 11 years old COVID resources

On this page, you will find resources for vaccinating 5 to 11-year-olds.

Visit page: 5 to 11 years old COVID resources


Comirnaty 12 years plus (purple cap) has been replaced with 2 grey cap vaccines

The Comirnaty 12+ purple cap vaccine has now been replaced by two grey top vaccines: 

  1. Comirnaty 30mcg 12+ grey cap, which replaces the purple cap for primary courses
  2. Comirnaty 15/15mcg grey cap, the bivalent vaccine which will be used for boosters.

Visit page for more details and resources: Comirnaty grey cap vaccines


Medsafe Comirnaty age 5-11-year-olds (orange cap)     

Medsafe Comirnaty grey caps

Comirnaty 30mcg 12+ Primary course

Comirnaty 15/15mcg 16+ Boosters.

Be careful to get the latest datasheets - here is the MedSafe datasheet search page.






    • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
    • Thompson M, Burgess J, Naleway A, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep, 2021.
    • Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. 2021.
    • Clancy, S. & Brown, W. (2008) Translation: DNA to mRNA to Protein. Nature Education 1(1):101
    • Comirnaty data sheet
    • Petousis-Harris H. Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Saf. 2020;43(12):1205-10.
    • Law B, Sturkenboom M. D2. 3 Priority list of adverse events of special interest: COVID-19. The Brighton Collaboration.
    • Shimbabukuro T, CDC-COVID-19 Vaccine Task Force. COVID-19 vaccine safety update. March 2021. 2021 1 March 2021.Available from:
    • UK Health Security Agency. (2021). COVID-19 vaccine surveillance report Week 40. [last update 7 October 2021; cited 14 October 2021] Available from…
    • Nordström P, Ballin M, Nordström A. Association between risk of COVID-19 infection in nonimmune individuals and COVID-19 immunity in their family members. JAMA Internal Medicine. 2021. doi: 10.1001/jamainternmed.2021.5814
    Last updated: 29 March 2023